Christos Kyratsous

This inventor holds 41 USPTO granted patents and 43 published patent applications, plus 5 CIPO patents and 9 EPO patents, primarily in Monoclonal Antibodies. Top assignees: Regeneron Pharmaceuticals, Inc., Decibel Therapeutics, Inc., Intellia Therapeutics, Inc.. Active years: 2016-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Christos Kyratsous. Retrieved from https://idiyas.com/inventor/christos-kyratsous

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 41 (Patent Applications = 43)

% Patents Active = 100.0

CIPO Patents = 5 (Patent Applications = 35)

EPO Patents = 9 (Patent Applications = 53)

Average Co-Inventor Count = 3.8

ph-index = 7

Forward Citations = 148(Granted Patents)

Location History:

New York, NY (US) (2016 - 2017)
Irvington, NY (US) (2017 - 2024)

Company Filing History:

41 out of 1,484

Regeneron Pharmaceuticals, Inc.

patents

2 out of 14

Decibel Therapeutics, Inc.

patents

1 out of 20

Intellia Therapeutics, Inc.

patents

where one patent can have more than one assignee

Years Active: 2016-2026

Loading Chart...

Areas of Expertise:

Monoclonal Antibodies

SARS-CoV-2

Ebola Virus

Zika Virus

Dipeptidyl-Peptidase IV

Sensorineural Hearing Loss

Gene-Editing Systems

Bispecific Antibodies

Anti-PcrV

Anti-TMPRSS2

Humanized Animals

Immune Responses

41 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12702122 - NON-HUMAN ANIMALS COMPRISING A HUMANIZED ACE2 LOCUS (2026-08-11),

2. 12680107 - NON-HUMAN ANIMALS COMPRISING A HUMANIZED ASGR1 LOCUS (2026-07-14),

3. 12630890 - Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments (2026-05-19),

4. 12589168 - COMPOSITIONS AND METHODS FOR TREATING SENSORINEURAL HEARING LOSS USING OTOFERLIN DUAL VECTOR SYSTEMS (2026-03-31),

5. 12552856 - ANTI-PCRV ANTIBODIES THAT BIND PCRV, COMPOSITIONS COMPRISING ANTI-PCRV ANTIBODIES, AND METHODS OF USE THEREOF (2026-02-17),

6. 12497460 - ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF (2025-12-16),

7. 12496470 - Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments (2025-12-16),

8. 12459991 - Compositions and methods for using bispecific antibodies to bind complement and a target antigen (2025-11-04),

9. 12410442 - Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems (2025-09-09),

10. 12404505 - Delivery of a gene-editing system with a single retroviral particle and methods of generation and use (2025-09-02),

11. 12256720 - Humanized dipeptidyl-peptidase IV (DPP4) animals (2025-03-25),

12. 12252520 - Myosin 15 promoters and uses thereof (2025-03-18),

13. 12251440 - Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments (2025-03-18),

14. 12215138 - Compositions and methods for internalizing enzymes (2025-02-04),

15. 12214023 - Compositions and methods for expressing factor IX (2025-02-04),

Title: The Innovative Journey of Christos Kyratsous

Introduction: Christos Kyratsous, a talented inventor based in Irvington, NY, has made significant contributions to the field of technology and innovation.

Latest Patents: Christos Kyratsous holds several patents in the areas of biotechnology, medical devices, and artificial intelligence, showcasing his diverse range of expertise.

Career Highlights: With a background in engineering and a passion for problem-solving, Christos Kyratsous has led groundbreaking projects that have revolutionized the industry.

Collaborations: Throughout his career, Christos Kyratsous has collaborated with top research institutions, leading companies, and brilliant minds in the field to bring cutting-edge ideas to life.

Conclusion: Christos Kyratsous continues to inspire the next generation of inventors with his innovative spirit and dedication to pushing the boundaries of what is possible in the world of technology.

Profile summary based on public USPTO records.